0001104659-20-082857.txt : 20200710
0001104659-20-082857.hdr.sgml : 20200710
20200710210025
ACCESSION NUMBER: 0001104659-20-082857
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200709
FILED AS OF DATE: 20200710
DATE AS OF CHANGE: 20200710
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Coffin Robert
CENTRAL INDEX KEY: 0001376492
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38596
FILM NUMBER: 201024164
MAIL ADDRESS:
STREET 1: C/O BIOVEX GROUP, INC.
STREET 2: 34 COMMERCE WAY
CITY: WOBURN
STATE: MA
ZIP: 10801
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Replimune Group, Inc.
CENTRAL INDEX KEY: 0001737953
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 822082553
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 500 UNICORN PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
BUSINESS PHONE: (781) 222-9600
MAIL ADDRESS:
STREET 1: 500 UNICORN PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
4
1
a4.xml
4
X0306
4
2020-07-09
0
0001737953
Replimune Group, Inc.
REPL
0001376492
Coffin Robert
C/O REPLIMUNE GROUP, INC.
500 UNICORN PARK
WOBURN
MA
01801
1
1
0
0
President & Chief R&D Officer
Common Stock
2020-07-09
4
S
0
145500
22.32
D
2048368
D
Common Stock
2020-07-09
4
S
0
24250
21.02
D
2024118
D
The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.8167 to $22.7299.
Following the sales reported on this Form 4, the reporting person continues to beneficially own 2,024,118 shares of the Issuer's common stock. The reporting person also holds options to acquire 977,599 shares of the Issuer's common stock, 384,438 of which are exercisable as of the date hereof.
/s/ Jean Franchi, attorney-in-fact
2020-07-10